Views
1287 of 1287 companies
| Company | Pipeline | Most advanced | Next readout |
|---|---|---|---|
 AC ImmuneACIU · Nasdaq | 4 assets: 4 Ph 2 | AFFITOPE PD01A / ACI-7104.056Phase 2 · Parkinson's Disease | 22 Dec 2026JNJ-64042056 · Phase 2 |
 Acadia PharmaceuticalsACAD · Nasdaq | 4 assets: 2 approved, 1 Ph 3, 1 Ph 2 | ACP-204Phase 3 · Alzheimer's Disease | Aug 2027ACP-211 · Phase 2 |
 AddpharmaPrivate | 4 assets: 1 Ph 3, 3 Ph 1 | AD-209Phase 3 · HypertensionPartial signal | None on record |
 Alphamab Oncology9966 · HKEX | 4 assets: 4 Ph 3 | JSKN003Phase 3 · HR+/HER2- Metastatic Breast Cancer | 30 Dec 2026JSKN003 · Phase 3 |
 Arcus BiosciencesRCUS · Nasdaq | 4 assets: 2 Ph 3, 2 Ph 1 | CasdatifanPhase 3 · Clear Cell Renal Cell Carcinoma | Nov 2026AB801 · Phase 1 |
 Arvinas Inc.ARVN · | 4 assets: 1 approved, 2 Ph 2, 1 other | ARV-766Phase 1/2 · Metastatic Castration-Resistant Prostate Cancer | 30 Nov 2026ARV-806 · Phase 1/2 |
 Ascletis Pharma1672 · HKEX | 4 assets: 3 Ph 3, 1 Ph 1 | DenifanstatPhase 3 · MASH / NASHReliable signal | Jul 2028ASC30 · Phase 3 |
 AtaiBeckley Inc.Private | 4 assets: 3 Ph 2, 1 other | BPL-003 (mebufotenin benzoate)Phase 2 · Major Depressive DisorderPartial signal | None on record |
 BeBetter Med688759 · SSE STAR Market | 4 assets: 2 Ph 3, 2 Ph 2 | BEBT-908Phase 3 · Multiple MyelomaWeak signal | Jun 2027BEBT-109 · Phase 2 |
 Beijing InnoCare Pharma Tech Co.9969 · HKEX | 4 assets: 3 Ph 3, 1 Ph 2 | ICP-488Phase 3 · PsoriasisPartial signal | 25 Nov 2026ICP-332 · Phase 3 |
 Beijing QL BiopharmaceuticalPrivate | 4 assets: 2 Ph 3, 1 Ph 2, 1 Ph 1 | ZT002Phase 3 · ObesityReliable signal | 3 Dec 2026zovaglutide · Phase 1 |
| 4 assets: 4 Ph 3 | stapokibartPhase 3 · Atopic DermatitisReliable signal | 11 Oct 2026HB1801 · Phase 2 | |
 Chipscreen Biosciences688321 · SSE | 4 assets: 2 Ph 3, 1 Ph 2, 1 Ph 1 | ChiglitazarPhase 3 · Type 2 DiabetesReliable signal | 26 Oct 2026Chiglitazar · Phase 1 |
| 4 assets: 2 Ph 2, 2 Ph 1 | CD123 targeted CAR-NK cellsPhase 1/2 · Acute Myeloid LeukemiaWeak signal | 31 Dec 2026BCMA-targeted Prime CAR-T cells (Chongqing Precision Biotech) · Phase 1/2 | |
 Corcept TherapeuticsCORT · Nasdaq | 4 assets: 2 approved, 2 Ph 2 | miricorilantPhase 2 · MASH / NASHWeak signal | 30 Oct 2026miricorilant · Phase 1 |
| 4 assets: 1 Ph 3, 3 Ph 1 | ZipalertinibPhase 3 · Non-Small Cell Lung Cancer | Nov 2026CLN-978 · Phase 1 | |
 CytokineticsCYTK · Nasdaq | 4 assets: 1 approved, 2 Ph 3, 1 other | Omecamtiv mecarbilPhase 3 · Heart FailureReliable signal | Sep 2027Omecamtiv mecarbil · Phase 3 |
 Denali TherapeuticsDNLI · Nasdaq | 4 assets: 2 Ph 3, 1 Ph 2, 1 Ph 1 | BIIB122 / DNL151 (LRRK2 inhibitor)Phase 3 · Parkinson's DiseasePartial signal | Feb 2027DNL628 · Phase 1 |
 Dr. Reddy's LaboratoriesRDY · NYSE | 4 assets: 4 approved | Approved assets only | 31 Mar 2027Eribulin mesylate · Phase 1/2 |
 DualityBio Inc.9606 · HKEX | 4 assets: 2 Ph 3, 2 Ph 2 | BNT324Phase 3 · Non-Small Cell Lung Cancer | Aug 2027DB-1303 · Phase 1/2 |
 Faeth Therapeutics, Inc.FTH · Nasdaq | 4 assets: 3 Ph 2, 1 other | SapanisertibPhase 2 · HR+/HER2- Metastatic Breast CancerWeak signal | Sep 2028Serabelisib · Phase 2 |
 Fate TherapeuticsFATE · Nasdaq | 4 assets: 2 Ph 2, 2 Ph 1 | FT819Phase 2 · Systemic Lupus Erythematosus | 30 Sep 2027FT819 · Phase 1 |
 Gan & Lee Pharmaceuticals603087 · SSE | 4 assets: 2 Ph 3, 2 Ph 2 | GZR18Phase 3 · ObesityPartial signal | 11 Dec 2026GZR18 · Phase 3 |
 Harrow, Inc.HROW · Nasdaq | 4 assets: 4 approved | Approved assets only | 4 Feb 2027Ranibizumab · Phase 3 |
 Henan Genuine BiotechPrivate | 4 assets: 1 Ph 3, 3 Ph 2 | AzvudinePhase 3 · HIVPartial signal | Dec 2026CL-197 · Phase 2 |
| 4 assets: 3 Ph 2, 1 Ph 1 | Hrain anti-BCMA CAR-TPhase 2 · Multiple MyelomaWeak signal | None on record | |
 Jacobio Pharmaceuticals1167 · HKEX | 4 assets: 2 Ph 3, 2 Ph 2 | GlecirasibPhase 3 · Non-Small Cell Lung CancerWeak signal | 31 Dec 2026JAB-23E73 · Phase 1/2 |
 Kissei Pharmaceutical4547 · TSE | 4 assets: 2 Ph 3, 2 Ph 2 | JR-131Phase 3 · Chronic Kidney DiseasePartial signal | None on record |
 Kodiak Sciences Inc.KOD · Nasdaq | 4 assets: 4 Ph 3 | KSI-301Phase 3 · Age-Related Macular DegenerationReliable signal | Feb 2027KSI-101 · Phase 3 |
 Krystal Biotech, Inc.KRYS · | 4 assets: 1 approved, 1 Ph 2, 2 Ph 1 | KB707Phase 1/2 · Non-Small Cell Lung Cancer | Dec 2026KB407 · Phase 1 |
 LG Chem051910 · KOSPI | 4 assets: 1 Ph 3, 2 Ph 2, 1 Ph 1 | GemigliptinPhase 3 · Type 2 DiabetesReliable signal | Nov 2027LB-LR1109 · Phase 1 |
 MallinckrodtPrivate | 4 assets: 4 approved | Approved assets only | None on record |
 ModernaMRNA · Nasdaq | 4 assets: 2 approved, 1 Ph 3, 1 Ph 2 | Intismeran AutogenePhase 3 · Non-Small Cell Lung Cancer | 31 Dec 2026elasomeran · Approved |
 Nuvalent, Inc.Private | 4 assets: 1 approved, 1 Ph 3, 1 Ph 1, 1 other | Neladalkib NVL-655Phase 3 · Non-Small Cell Lung Cancer | Jan 2027NVL-330 · Phase 1 |
 Pierre Fabre MedicamentPrivate | 4 assets: 3 Ph 2, 1 Ph 1 | STX-241Phase 1/2 · Non-Small Cell Lung Cancer | 20 Nov 2027STX-241 · Phase 1/2 |
 Precigen, IncPGEN · | 4 assets: 2 Ph 2, 1 Ph 1, 1 other | goraderminogene ceraplasmidPhase 2 · Recurrent Respiratory Papillomatosis | None on record |
 REGENXBIO Inc.RGNX · Nasdaq | 4 assets: 4 Ph 3 | RGX-314Phase 3 · Age-Related Macular DegenerationWeak signal | Dec 2026Surabgene Lomparvovec (ABBV-RGX-314) · Phase 2/3 |
 Radiopharm Theranostics, LtdRADX · Nasdaq | 4 assets: 1 Ph 2, 1 Ph 1, 2 other | 177Lu-BetaBartPhase 1/2 · Non-Small Cell Lung Cancer | Dec 2027177Lu-RAD204 · Phase 1 |
 Rhythm PharmaceuticalsRYTM · Nasdaq | 4 assets: 1 approved, 3 Ph 2 | LB54640Phase 2 · ObesityPartial signal | 31 Oct 2026setmelanotide · Phase 2 |
 ServierPrivate | 4 assets: 1 Ph 3, 3 Ph 2 | IvosidenibPhase 3 · Acute Myeloid Leukemia | 31 Dec 2026Ivosidenib · Phase 1 |
| 4 assets: 2 Ph 3, 1 Ph 2, 1 Ph 1 | Foritinib succinatePhase 3 · Non-Small Cell Lung Cancer | 1 Dec 2026FCN-338 · Phase 2 | |
| 4 assets: 2 Ph 3, 2 Ph 2 | rESPPhase 3 · Chronic Kidney DiseasePartial signal | Dec 2026SSGJ-706 · Phase 2 | |
 Simcere Pharmaceutical2096 · HKEX | 4 assets: 3 Ph 3, 1 Ph 1 | EndostarPhase 3 · Non-Small Cell Lung CancerPartial signal | 30 Sep 2027SIM0500 · Phase 1 |
 Spyre TherapeuticsSYRE · Nasdaq | 4 assets: 4 Ph 2 | SPY001Phase 2 · Ulcerative Colitis | 31 Oct 2026SPY072 · Phase 2 |
 Tango TherapeuticsTNGX · Nasdaq | 4 assets: 4 Ph 2 | TNG260Phase 1/2 · Non-Small Cell Lung Cancer | 31 Mar 2027TNG456 · Phase 1/2 |
 Tasly Pharmaceutical Group600535 · SSE | 4 assets: 4 Ph 2 | QiShenYiQiPhase 2 · Heart FailurePartial signal | 31 Dec 2026Jia Shen Tablet · Phase 2 |
 Vifor PharmaPrivate | 4 assets: 3 approved, 1 Ph 3 | PatiromerPhase 3 · Heart FailurePartial signal | 15 Aug 2029Difelikefalin · Phase 2 |
 Wave Life SciencesWVE · Nasdaq | 4 assets: 4 Ph 2 | WVE-003Phase 1/2 · Huntington's Disease | Dec 2027WVE-007 · Phase 1/2 |
 Xuanzhu Biopharmaceutical2575 · HKEX | 4 assets: 2 Ph 3, 1 Ph 2, 1 Ph 1 | XZP-3621Phase 3 · Non-Small Cell Lung CancerPartial signal | None on record |
 Zai LabZLAB · Nasdaq | 4 assets: 2 approved, 1 Ph 2, 1 Ph 1 | ZL-1102Phase 2 · PsoriasisPartial signal | 26 Nov 2026Niraparib · Phase 3 |
 iCell Gene TherapeuticsPrivate | 4 assets: 2 Ph 2, 2 Ph 1 | ICG318Phase 2 · Systemic Lupus Erythematosus | 31 Dec 2027ICG318 · Phase 1 |
 Abbisko Therapeutics2256 · HKEX | 3 assets: 2 Ph 2, 1 Ph 1 | ABSK043Phase 2 · Non-Small Cell Lung Cancer | Mar 2027ABSK112 · Phase 1 |
 Aktis Oncology, Inc.AKTS · | 3 assets: 2 Ph 1, 1 other | 225Ac-AKY-1189Phase 1 · Non-Small Cell Lung Cancer | Dec 2027225Ac-AKY-1189 · Phase 1 |
 AlectorALEC · Nasdaq | 3 assets: 2 Ph 2, 1 other | AL002Phase 2 · Alzheimer's Disease | 15 Sep 2028GSK4527226 (AL101) · Phase 2 |
 Annexon, Inc.ANNX · Nasdaq | 3 assets: 3 Ph 3 | ANX007Phase 3 · Age-Related Macular DegenerationPartial signal | 31 Oct 2026ANX007 · Phase 3 |
 Apogee TherapeuticsPrivate | 3 assets: 1 Ph 2, 1 Ph 1, 1 other | ZumilokibartPhase 2 · Atopic Dermatitis | Nov 2026Zumilokibart · Phase 2 |
 Apollo TherapeuticsPrivate | 3 assets: 2 Ph 2, 1 Ph 1 | camoteskimabPhase 2 · Atopic DermatitisPartial signal | 1 Mar 2027APL-4098 · Phase 1 |
 Aquestive Therapeutics, Inc.AQST · Nasdaq | 3 assets: 1 approved, 1 Ph 3, 1 other | Diazepam (Libervant)Phase 3 · EpilepsyWeak signal | None on record |
 Avenzo Therapeutics, Inc.Private | 3 assets: 3 Ph 2 | AVZO-021Phase 1/2 · HR+/HER2- Metastatic Breast Cancer | 31 Jan 2028AVZO-021 · Phase 1/2 |
 Beam Therapeutics Inc.BEAM · Nasdaq | 3 assets: 2 Ph 2, 1 other | BEAM-301Phase 1/2 · Glycogen Storage Disease Type Ia | 30 Dec 2027BEAM-301 · Phase 1/2 |
| 3 assets: 3 Ph 1 | IM21 CAR-T cellsPhase 1 · Multiple MyelomaWeak signal | None on record | |
 Bio-Path Holdings, Inc.BPTH · OTC | 3 assets: 1 Ph 2, 2 Ph 1 | BP1001Phase 2 · Acute Myeloid LeukemiaWeak signal | Mar 2027BP1002; Liposomal Bcl-2 Antisense Oligodeoxynucleotide · Phase 1 |
 Bio-Thera Solutions688177 · SSE STAR Market | 3 assets: 3 approved | Approved assets only | None on record |
 BioAtla, Inc.BCAB · OTC | 3 assets: 3 Ph 2 | CAB-AXL-ADCPhase 2 · Non-Small Cell Lung CancerWeak signal | None on record |
 BioNTechBNTX · Nasdaq | 3 assets: 1 Ph 2, 2 Ph 1 | BNT116Phase 2 · Non-Small Cell Lung Cancer | Nov 2026BNT351 · Phase 1 |
 BioconBIOCON · NSE | 3 assets: 3 approved | Approved assets only | None on record |
 Biomea FusionBMEA · Nasdaq | 3 assets: 1 Ph 2, 2 Ph 1 | BMF-219Phase 2 · Type 2 DiabetesPartial signal | Mar 2027BMF-219 · Phase 2 |
 Candid TherapeuticsPrivate | 3 assets: 3 Ph 1 | cizutamigPhase 1 · Systemic Lupus Erythematosus | 1 Jun 2027CND261 · Phase 1 |
 Caribou Biosciences, Inc.CRBU · Nasdaq | 3 assets: 3 Ph 1 | CB-010Phase 1 · B-Cell Non-Hodgkin Lymphoma | Dec 2027CB-011 · Phase 1 |
 Celgene CorporationPrivate | 3 assets: 1 approved, 1 Ph 3, 1 Ph 2 | SotaterceptPhase 3 · HypertensionPartial signal | 3 Apr 2028Sotatercept · Approved |
 Cogent Biosciences, Inc.COGT · Nasdaq | 3 assets: 1 Ph 3, 2 Ph 1 | bezuclastinibPhase 3 · Gastrointestinal Stromal Tumor | May 2028CGT4255 · Phase 1 |
| 3 assets: 3 approved | Approved assets only | None on record | |
 Corvus PharmaceuticalsCRVS · Nasdaq | 3 assets: 2 Ph 3, 1 Ph 2 | soquelitinibPhase 3 · Peripheral T-Cell LymphomaPartial signal | Jun 2027soquelitinib · Phase 2 |
 Disc MedicineIRON · Nasdaq | 3 assets: 1 Ph 3, 1 Ph 2, 1 Ph 1 | BitopertinPhase 3 · Erythropoietic Protoporphyria | May 2027DISC-0974 · Phase 1/2 |
 Ellipses PharmaPrivate | 3 assets: 3 Ph 2 | EP0031Phase 1/2 · Non-Small Cell Lung Cancer | Mar 2027EP0031 · Phase 1/2 |
 Emergent BioSolutionsEBS · NYSE | 3 assets: 3 approved | Approved assets only | None on record |
 Esperion TherapeuticsPrivate | 3 assets: 3 approved | Approved assets only | None on record |
 Essen BiotechPrivate | 3 assets: 3 Ph 2 | CD123/CD33 CARTPhase 1/2 · Acute Myeloid Leukemia | 28 Dec 2027EB-SELECT Single-Target CAR-NK Cells · Phase 1/2 |
 ExelixisEXEL · Nasdaq | 3 assets: 1 approved, 1 Ph 3, 1 Ph 1 | ZanzalintinibPhase 3 · Clear Cell Renal Cell Carcinoma | 23 Nov 2026XB010 · Phase 1 |
 GI Innovation, Inc.358570 · KOSDAQ | 3 assets: 3 Ph 2 | GI-101Phase 1/2 · Non-Small Cell Lung Cancer | Feb 2027GI-108 · Phase 1/2 |
 GenfitGNFT · Euronext Paris | 3 assets: 1 approved, 1 Ph 2, 1 other | GNS561Phase 1/2 · Cholangiocarcinoma with KRAS Mutation | Dec 2027GNS561 · Phase 1/2 |
Guangzhou JOYO PharmaPrivate | 3 assets: 1 Ph 3, 2 Ph 2 | JYP0322Phase 3 · Non-Small Cell Lung Cancer | 31 Oct 2027JYP0322 · Phase 3 |
 HK inno.N Corporation195940 · KOSDAQ | 3 assets: 2 Ph 3, 1 Ph 2 | CJ-30060Phase 3 · HypertensionPartial signal | None on record |
| 3 assets: 1 Ph 3, 1 Ph 2, 1 Ph 1 | TLL-018Phase 3 · PsoriasisPartial signal | 31 Dec 2026TLL-018 · Phase 3 | |
 Huahui HealthPrivate | 3 assets: 1 Ph 2, 2 Ph 1 | HH-003 (Libevitug)Phase 2 · Chronic Hepatitis B | Aug 2027HH160 · Phase 1 |
 IRLAB TherapeuticsPrivate | 3 assets: 3 Ph 2 | Mesdopetam (IRL790)Phase 2 · Parkinson's DiseasePartial signal | None on record |
 Immunome, Inc.IMNM · | 3 assets: 1 Ph 1, 2 other | IM-1617Phase 1 · Non-Small Cell Lung Cancer | Jan 2029IM-1617 · Phase 1 |
 Indivior Pharmaceuticals, Inc.INDV · Nasdaq | 3 assets: 3 approved | Approved assets only | None on record |
 Innate PharmaIPH · Euronext Paris | 3 assets: 1 Ph 3, 1 Ph 1, 1 other | MonalizumabPhase 3 · Non-Small Cell Lung CancerPartial signal | Apr 2028IPH4502 · Phase 1 |
 Intra-Cellular TherapiesPrivate | 3 assets: 1 approved, 2 Ph 2 | Lenrispodun (ITI-214)Phase 2 · Parkinson's DiseasePartial signal | 16 Mar 2027ITI-1284 · Phase 2 |
 Kura Oncology, Inc.KURA · Nasdaq | 3 assets: 2 Ph 3, 1 Ph 1 | TipifarnibPhase 3 · Clear Cell Renal Cell Carcinoma | Dec 2026Ziftomenib · Phase 1 |
 LEO PharmaPrivate | 3 assets: 2 approved, 1 Ph 2 | temtokibartPhase 2 · Atopic DermatitisReliable signal | 20 Oct 2026tralokinumab · Phase 3 |
| 3 assets: 2 Ph 3, 1 Ph 2 | MB12Phase 3 · Non-Small Cell Lung CancerPartial signal | None on record | |
 Ligand PharmaceuticalsLGND · Nasdaq | 3 assets: 3 approved | Approved assets only | 1 Mar 2027ensifentrine · Phase 2 |
 Lundbeck LLCPrivate | 3 assets: 3 approved | Approved assets only | None on record |
 Madrigal PharmaceuticalsMDGL · Nasdaq | 3 assets: 1 approved, 1 Ph 2, 1 other | PF-06865571Phase 2 · MASH / NASHPartial signal | Dec 2026Resmetirom · Phase 3 |
 MannKind CorporationMNKD · Nasdaq | 3 assets: 3 approved | Approved assets only | Mar 2027Afrezza · Phase 2 |
 MesoblastMESO · Nasdaq | 3 assets: 1 approved, 1 Ph 3, 1 Ph 2 | rexlemestrocel-LPhase 3 · Heart Failure | Jul 2027rexlemestrocel-L · Phase 3 |
 Nanjing Leads Biolabs Co.,Ltd9887 · HKEX | 3 assets: 1 Ph 3, 1 Ph 2, 1 Ph 1 | LBL-024Phase 3 · Non-Small Cell Lung Cancer | 20 Oct 2026LBL-034 · Phase 1/2 |
 Newsoara BiopharmaPrivate | 3 assets: 2 Ph 3, 1 Ph 1 | HPP737Phase 3 · PsoriasisPartial signal | 1 Dec 2026HY1272 · Phase 1 |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov).